10x Genomics, Inc. (TXG) SEC filings

TXGNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/30118% above fair value

$58.19−0.91 (-1.54%)

Close on Nov 13, 2026Market cap $7.58BP/E –Yield –

SEC filings

40 of 10x Genomics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 6, 2026	SEC EDGAR
Current report	8-K	Nov 5, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Oct 28, 2026	Nov 2, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 7, 2026	SEC EDGAR
Current report	8-K	Aug 6, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Jun 4, 2026	Jun 8, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 8, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 7, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 4, 2026	Apr 24, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Feb 13, 2026	SEC EDGAR
Current report	8-K	Feb 12, 2026	Feb 12, 2026	SEC EDGAR
Current report	8-K	Jan 11, 2026	Jan 12, 2026	SEC EDGAR
Current report	8-K	Nov 12, 2025	Nov 14, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 7, 2025	SEC EDGAR
Current report	8-K	Nov 6, 2025	Nov 6, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 8, 2025	SEC EDGAR
Current report	8-K	Aug 7, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Jun 3, 2025	Jun 5, 2025	SEC EDGAR
Current report	8-K	May 12, 2025	May 14, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 9, 2025	SEC EDGAR
Current report	8-K	May 6, 2025	May 8, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 3, 2025	Apr 14, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Feb 13, 2025	SEC EDGAR
Current report	8-K	Feb 12, 2025	Feb 12, 2025	SEC EDGAR
Current report	8-K	Jan 12, 2025	Jan 13, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Oct 29, 2024	SEC EDGAR
Current report	8-K	Oct 24, 2024	Oct 29, 2024	SEC EDGAR
Current report	8-K	Oct 9, 2024	Oct 9, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 8, 2024	SEC EDGAR
Current report	8-K	Aug 6, 2024	Aug 8, 2024	SEC EDGAR
Current report	8-K	Jul 10, 2024	Jul 11, 2024	SEC EDGAR
Current report	8-K	Jun 18, 2024	Jun 20, 2024	SEC EDGAR
Current report	8-K	Jun 11, 2024	Jun 13, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	Apr 30, 2024	SEC EDGAR
Current report	8-K	Apr 30, 2024	Apr 30, 2024	SEC EDGAR
Proxy statement	DEF 14A	Jun 11, 2024	Apr 26, 2024	SEC EDGAR
Annual report	10-K	Dec 31, 2023	Feb 15, 2024	SEC EDGAR
Current report	8-K	Feb 15, 2024	Feb 15, 2024	SEC EDGAR
Current report	8-K	Jan 15, 2024	Jan 16, 2024	SEC EDGAR
Current report	8-K	Jan 8, 2024	Jan 8, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in 10x Genomics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is TXG.

Compare: TXG vs PACB · TXG vs CTKB · TXG vs QTRX · TXG vs ILMN · TXG vs RVTY

Revenue growth-3.6% · median 5.5%

Gross margin71.9% · median 49.6%

Operating margin-11.7% · median -21.1%

Net margin-10.8% · median -39.1%

Company	Revenue	Growth
ILMN	$4.54B	+5.8%
RVTY	$2.94B	+4.6%
TXG	$618.58M	-3.6%
CTKB	$207.65M	+5.5%
PACB	$161.39M	+4.4%
QTRX	$148.15M	+13.8%

Company

Next earnings (est.): Feb 11, 2027, after close
Exchange: Nasdaq
Industry: Laboratory Analytical Instruments
Fiscal year ends: December 31
Employees: 1,178
Held by institutions: 98.7%
Auditor: Ernst & Young LLP
SEC CIK: 1770787

Advertisement
300 × 250

See a number that looks wrong?